The article presents the results of studying the impact of α-glucosidase inhibitors on body weight and main carbohydrate metabolism indicators. The authors note the positive effects of drugs from this group on all components of metabolic syndrome, safety for the body, absence of serious contraindications and low level of hypoglycemia. Voglibose as representative of α-glucosidase inhibitors can be effectively used in combination with metformin, as well as together with insulin therapy.